Expression analysis of putative stem cell markers in human benign and malignant prostate

Prostate

Volumn 71, Issue 1, 2011, Pages 18-25

  Ugolkov, Andrey V ^a   Eisengart, Laurie J ^a   Luan, Chunyan ^a   Yang, Ximing J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

EZH2; prostate cancer; SOX2; stem cells

Indexed keywords

CD133 ANTIGEN; HERMES ANTIGEN; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR SOX2;

ARTICLE; CANCER GRADING; CANCER STEM CELL; CONTROLLED STUDY; EMBRYONIC STEM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION;

ADENOCARCINOMA; ANTIGENS, CD; ANTIGENS, CD44; DNA-BINDING PROTEINS; GLYCOPROTEINS; HUMANS; MALE; NEOPLASTIC STEM CELLS; OCTAMER TRANSCRIPTION FACTOR-3; PEPTIDES; PROSTATE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; SOXB1 TRANSCRIPTION FACTORS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 78649605417     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21217     Document Type: Article

References (40)

1. Baade PD, Youlden DR, Krnjacki LJ,. International epidemiology of prostate cancer: Geographical distribution and secular trends. Mol Nutr Food Res 2009; 53 (2): 171-184.
2. Lawson DA, Witte ON,. Stem cells in prostate cancer initiation and progression. J Clin Invest 2007; 117 (8): 2044-2050.
3. Alison MR, Lovell MJ, Direkze NC, Wright NA, Poulsom R,. Stem cell plasticity and tumour formation. Eur J Cancer 2006; 42: 1247-1256.
4. Pesce M, Scholer HR,. Oct4: Control of totipotency and germline determination. Mol Reprod Dev 2000; 55 (4): 452-457.
5. Monk M, Holding C,. Human embryonic genes re-expressed in cancer cells. Oncogene 2001; 20: 8085-8091.
6. Looijenga LH, Stoop H, de Leeuw HP, de Gouveia Brazao CA, Gillis AJ, van Roozendaal KE, van Zoelen EJ, Weber RF, Wolffenbuttel KP, van Dekken H, Honecker F, Bokemeyer C, Perlman EJ, Schneider DT, Kononen J, Sauter G, Oosterhuis JW,. POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res 2003; 63 (9): 2244-2250.
7. Fong H, Hohenstein KA, Donovan PJ,. Regulation of self-renewal and pluripotency by Sox2 in human embryonic stem cells. Stem Cells 2008; 26: 1931-1938.
8. Gangemi RM, Griffero F, Marubbi D, Perera M, Capra MC, Malatesta P, Ravetti GL, Zona GL, Daga A, Corte G,. SOX2 silencing in glioblastoma tumor initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells 2009; 27 (1): 40-48.
9. Santos-Rosa H, Caldas C,. Chromatin modifier enzymes, the histone code and cancer. Eur J Cancer 2005; 41: 2381-2402.
10. Suvà ML, Riggi N, Janiszewska M, Radovanovic I, Provero P, Stehle JC, Baumer K, Le Bitoux MA, Marino D, Cironi L, Marquez VE, Clément V, Stamenkovic I,. EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res 2009; 69 (24): 9211-9218.
11. Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, Morey L, Van Eynde A, Bernard D, Vanderwinden JM, Bollen M, Esteller M, Di Croce L, de Launoit Y, Fuks F,. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006; 439: 871-874.
12. Krause DS, Lazarides K, von Andrian UH, Van Etten RA,. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nature Med 2006; 12 (10): 1175-1180.
13. Marhaba R, Zoller M,. CD44 in cancer progression: Adhesion, migration and growth regulation. J Mol Histol 2004; 35: 211-231.
14. Georgolios A, Batistatou A, Charalabopoulos A, Manolopoulos L, Charalabopoulos K,. The role of CD44 adhesion molecule in oral cavity cancer. Exp Oncol 2006; 28: 94-98.
15. Stavropoulos NE, Filliadis I, Ioachim E, Michael M, Mermiga E, Hastazeris K, Nseyo UO,. CD44 standard form expression as a predictor of progression in high risk superficial bladder tumors. Int Urol Nephrol 2001; 33: 479-483.
16. Liu J, Jiang G,. CD44 and hematologic malignancies. Cell Mol Immunol 2006; 3: 359-365.
17. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, Reilly JG, Chandra D, Zhou J, Claypool K, Coghlan L, Tang DG,. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006; 25: 1696-1708.
18. Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT,. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 2004; 117: 3539-3545.
19. Skacel M, Skilton B, Pettay JD, Tubbs RR,. Tissue microarrays: A powerful tool for high-throughput analysis of clinical specimens: A review of the method with validation data. Applied Immunohistochem Mol Morphol 2002; 10: 1-6.
20. Lin F, Yang W, Betten M, Teh BT, Yang XJ,. Expression of S-100 protein in renal cell neoplasms. Hum Pathol 2006; 37: 460-470.
21. Reya T, Morrison SJ, Clarke MF, Weissman IL,. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
22. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM,. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006; 66 (19): 9339-9344.
23. Nagabhushan M, Pretlow TG, Guo YJ, Amini SB, Pretlow TP, Sy MS,. Altered expression of CD44 in human prostate cancer during progression. Am J Clin Pathol 1996; 106: 647-651.
24. Kallakury BV, Yang F, Figge J, Smith KE, Kausik SJ, Tacy NJ, Fisher HA, Kaufman R, Figge H, Ross JS,. Decreased levels of CD44 protein and mRNA in prostate carcinoma. Correlation with tumor grade and ploidy. Cancer 1996; 78 (7): 1461-1469.
25. Simon RA, di Sant'Agnese PA, Huang LS, Xu H, Yao JL, Yang Q, Liang S, Liu J, Yu R, Cheng L, Oh WK, Palapattu GS, Wei J, Huang J,. CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers. Hum Pathol 2009; 40: 252-258.
26. De Marzo AM, Bradshaw C, Sauvageot J, Epstein JI, Miller GJ,. CD44 and CD44v6 downregulation in clinical prostatic carcinoma: Relation to Gleason grade and cytoarchitecture. Prostate 1998; 34: 162-168.
27. Paradis V, Eschwege P, Loric S, Dumas F, Ba N, BenoAët G, Jardin A, Bedossa P,. De novo expression of CD44 in prostate carcinoma is correlated with systemic dissemination of prostate cancer. J Clin Pathol 1998; 51: 798-802.
28. Wognum AW, Eaves AC, Thomas TE,. Identification and isolation of hematopoietic stem cells. Arch Med Res 2003; 34 (6): 461-475.
29. Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY,. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008; 27 (12): 1749-1758.
30. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS,. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006; 5: 67.
31. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ,. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65 (23): 10946-10951.
32. Pesce M, Scholer HR,. Oct4: Control of totipotency and germline determination. Mol Reprod Dev 2000; 55 (4): 452-457.
33. Zangrossi S, Marabese M, Broggini M, Giordano R, D'Erasmo M, Montelatici E, Intini D, Neri A, Pesce M, Rebulla P, Lazzari L,. Oct-4 expression in adult human differentiated cells challenges its role as a pure stem cell marker. Stem Cells 2007; 25 (7): 1675-1680.
34. Tai MH, Chang CC, Kiupel M, Webster JD, Olson LK, Trosko JE,. Oct4 expression in adult human stem cells: Evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis 2005; 26 (2): 495-502.
35. O'Carroll D, Erhardt S, Pagani M, Barton SC, Surani MA, Jenuwein T,. The polycomb-group gene Ezh2 is required for early mouse development. Mol Cell Biol 2001; 21: 4330-4336.
36. Boyer LA, Plath K, Zeitlinger J, Brambrink T, Medeiros LA, Lee TI, Levine SS, Wernig M, Tajonar A, Ray MK, Bell GW, Otte AP, Vidal M, Gifford DK, Young RA, Jaenisch R,. Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature 2006; 441: 349-353. (Pubitemid 44050199)
37. Abbosh PH, Montgomery JS, Starkey JA, Novotny M, Zuhowski EG, Egorin MJ, Moseman AP, Golas A, Brannon KM, Balch C, Huang TH, Nephew KP,. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells. Cancer Res 2006; 66: 5582-5591.
38. Fujii S, Ochiai A,. Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells. Cancer Sci 2008; 99: 738-746.
39. Ougolkov AV, Bilim VN, Billadeau DD,. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2. Clin Cancer Res 2008; 14 (21): 6790-6796.
40. Tang DG, Patrawala L, Calhoun T, Bhatia B, Choy G, Schneider-Broussard R, Jeter C,. Prostate cancer stem/progenitor cells: Identification, characterization, and implications. Mol Carcinog 2007; 46: 1-14.